Mortality of adult patients due to sepsis and septic shock in South Korea: a systematic review and metaanalysis
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Namgung, Myeong | - |
dc.contributor.author | Ahn, Chiwon | - |
dc.contributor.author | Park Yeonkyung | - |
dc.contributor.author | Kwak, Il-Youp | - |
dc.contributor.author | Lee, Jungguk | - |
dc.contributor.author | Won, Moonho | - |
dc.date.accessioned | 2024-01-09T02:38:02Z | - |
dc.date.available | 2024-01-09T02:38:02Z | - |
dc.date.issued | 2023-06 | - |
dc.identifier.issn | 2383-4625 | - |
dc.identifier.issn | 2383-4625 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/69774 | - |
dc.description.abstract | Objective: To evaluate mortality from sepsis and septic shock in Korea during the past 10 years, we conducted a systematic review and meta-analysis. Methods: We searched six databases for studies on mortality from sepsis and septic shock in adult patients. Primary outcomes were 28- or 30-day mortality and in-hospital mortality from sepsis and septic shock. To assess the risk of bias, we used the Newcastle-Ottawa Scale and Risk of Bias 2 tools. The protocol is registered in PROSPERO (No. CRD42022365739). Results: A total of 61 studies were included. The mortality rates from sepsis and septic shock at 28 or 30 days were 22.7% (95% confidence interval [CI], 20.0%–25.6%; I2=89%) and 27.6% (95% CI, 22.3%–33.5%; I2=98%), respectively, according to the Sepsis-3 criteria. Furthermore, in accordance with the Sepsis-3 criteria, the in-hospital mortality rates were 28.1% (95% CI, 25.2%–31.1%; I2=87%) and 34.3% (95% CI, 27.2%–42.2%; I2=97%), respectively. Conclusion: The mortality rates from sepsis and septic shock in Korea are high. In the case of septic shock, the in-hospital mortality rate is approximately 30%. | - |
dc.format.extent | 15 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | 대한응급의학회 | - |
dc.title | Mortality of adult patients due to sepsis and septic shock in South Korea: a systematic review and metaanalysis | - |
dc.type | Article | - |
dc.identifier.doi | 10.15441/ceem.23.005 | - |
dc.identifier.bibliographicCitation | Clinical and Experimental Emergency Medicine, v.10, no.2, pp 157 - 171 | - |
dc.identifier.kciid | ART002972404 | - |
dc.description.isOpenAccess | Y | - |
dc.identifier.wosid | 001030103900006 | - |
dc.identifier.scopusid | 2-s2.0-85164961594 | - |
dc.citation.endPage | 171 | - |
dc.citation.number | 2 | - |
dc.citation.startPage | 157 | - |
dc.citation.title | Clinical and Experimental Emergency Medicine | - |
dc.citation.volume | 10 | - |
dc.type.docType | Review | - |
dc.publisher.location | 대한민국 | - |
dc.subject.keywordAuthor | Sepsis | - |
dc.subject.keywordAuthor | Septic shock | - |
dc.subject.keywordAuthor | Mortality | - |
dc.subject.keywordAuthor | Republic of Korea | - |
dc.subject.keywordAuthor | Meta-analysis | - |
dc.subject.keywordPlus | CRITICALLY-ILL PATIENTS | - |
dc.subject.keywordPlus | INTERNATIONAL CONSENSUS DEFINITIONS | - |
dc.subject.keywordPlus | GELATINASE-ASSOCIATED LIPOCALIN | - |
dc.subject.keywordPlus | CLINICAL-OUTCOMES | - |
dc.subject.keywordPlus | TERM MORTALITY | - |
dc.subject.keywordPlus | MUSCLE MASS | - |
dc.subject.keywordPlus | PROENKEPHALIN | - |
dc.subject.keywordPlus | PROGNOSIS | - |
dc.subject.keywordPlus | CAMPAIGN | - |
dc.subject.keywordPlus | SCORE | - |
dc.relation.journalResearchArea | Emergency Medicine | - |
dc.relation.journalWebOfScienceCategory | Emergency Medicine | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | esci | - |
dc.description.journalRegisteredClass | kci | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
84, Heukseok-ro, Dongjak-gu, Seoul, Republic of Korea (06974)02-820-6194
COPYRIGHT 2019 Chung-Ang University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.